Last update 22 Mar 2025

Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine, Genetically engineered subunit vaccine
Synonyms
Recombinant COVID19 vaccine (Sf9 cells) (bivalent), 威克欣二价, WSK-V101C
Target
SARS-CoV-2 S protein
Action
inhibitors, stimulants
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors), Immunostimulants
Therapeutic Areas
Infectious DiseasesRespiratory Diseases
Active Indication
COVID-19
Inactive Indication-
Originator Organization
West China HospitalWest China HospitalChengdu Weisk Biopharmaceutical Co., Ltd.Chengdu Weisk Biopharmaceutical Co., Ltd.
Active Organization
Chengdu Weisk Biopharmaceutical Co., Ltd.Chengdu Weisk Biopharmaceutical Co., Ltd.West China HospitalWest China Hospital
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)
NCT05911048
/ Not yet recruitingPhase 2
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) in Booster Vaccination in Healthy Population 18 Years Old of Age and Above
ChiCTR2300073056
/ SuspendedPhase 2IIT
A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
100 Clinical Results associated with Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)
Login to view more data
100 Translational Medicine associated with Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)
Login to view more data
100 Patents (Medical) associated with Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)
Login to view more data
100 Deals associated with Recombinant protein COVID-19 vaccine (bivalent) (WestVac Biopharma)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 2-
Chengdu Weisk Biopharmaceutical Co., Ltd.Chengdu Weisk Biopharmaceutical Co., Ltd.
30 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free